SimBioSys
Latest round
- Series A
Last raised
- Oct 2021
Total raised
- $15M
Investors
- 5
About SimBioSys
SimBioSys, Inc.Founded in 2018 and headquartered in Chicago, US, SimBioSys, Inc. develops innovative tools for cancer surgeons.SimBioSys specializes in advanced visualization and diagnostic technology aimed at revolutionizing precision medicine within oncology.S. FDA clearance and is specifically designed to assist breast cancer surgeons in the preoperative planning of procedures such as breast conservation surgery. TumorSight Viz transforms traditional 2D DCE-MRI studies into interactive 3D models, facilitating crucial calculations such as tumor volume and proximity to anatomical features. This technology addresses the complexity of tumor heterogeneity, enabling clinicians to visualize tumors in their entirety—beyond standard biopsies and pathology slides. The company serves a range of clients, including top cancer centers and healthcare professionals across the United States, aiming to improve patient outcomes via individualization of treatment strategies.SimBioSys engages in B2B transactions primarily with healthcare institutions and professionals, providing subscription-based access to their suite of diagnostic tools. Revenue is generated through partnerships with leading cancer centers and healthcare systems, allowing these organizations to integrate TumorSight products into their clinical workflows. The pricing structure includes different tiers based on the specific tool utilized, with flagship offerings like TumorSight Viz forming the backbone of their commercial strategy. These transactions are facilitated through direct contracts with hospitals and clinics, establishing a reliable revenue stream as healthcare providers seek innovative solutions to improve cancer treatment planning and patient management.In October 2021, SimBioSys, Inc. The company plans to design and launch upcoming products targeting enhanced diagnostic capabilities, with specific attention to their integration into new market segments.S. healthcare sector, with strategies aimed at entering international markets by 2024.
Who invested in SimBioSys
5 investors across 1 round
See all investors in SimBioSys
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Oct 26, 2021
Amount
$15M
Investors
Questions about SimBioSys
Who invested in SimBioSys?
SimBioSys has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has SimBioSys raised?
SimBioSys has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did SimBioSys last raise money?
SimBioSys's most recent round on record is a Series A, in Oct 2021.
What does SimBioSys do?
SimBioSys is a biotechnology company.
Where is SimBioSys headquartered?
SimBioSys is headquartered in Chicago, US.
Which VCs invest in companies like SimBioSys?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at SimBioSys's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like SimBioSys? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.